Gastric Cancer Clinical Trial
Official title:
A Multi-Institutional Chart Review to Compare the Outcomes of Robotic, Laparoscopic and Open Surgery for Gastric Cancer.
Gastric cancer represents a great challenge for health care providers and requires a
multidisciplinary context in which surgery plays a main role.
Minimally invasive surgery has been progressively developed, first with the advent of
laparoscopy and more recently with the spread of robotic systems, but a number of issues are
currently being debated, including the limitations in performing effective extended lymph
node dissections and, in this context, the real advantages of using the robotic systems, the
possible role for the Advanced Gastric Cancer, the reproducibility of completely
intracorporeal techniques and the oncological results achievable during follow-up.
A multicenter study with a large number of patients is now needed to further investigate the
safety and efficacy as well as long-term outcomes of robotic surgery, traditional laparoscopy
and the open approach.
Overall purpose:
The Overall purpose is to develop a multi-institutional database comprising information
regarding surgical, clinical and oncological features of patients undergoing surgery for
gastric cancer with robotic, laparoscopic or open approaches and subsequent follow-up at
participating centers.
General study design:
The registry will be established by retrospectively identifying subjects with gastric cancer
treated at the participating centers.
Information gathered will be obtained from existing data and records, diagnostic tests and
surgical interventions.
Information will be collected and recorded by all institutes through a specific online shared
system.
Main objectives:
- To determine the surgical, clinical, and oncological outcomes in both the short and long
term
- To compare results according to the type of intervention, device used and manner of
execution of different surgical phases
- To relate results of different surgeries with baseline characteristics of patients and
stage of disease
Clinical relevance:
Studies that reported results of minimally invasive surgery for gastric cancer and recent
meta-analysis emphasize the need for large trials.
A further consideration in this field regards the need of numerous patients to reach a
statistical significance on surgical, clinical and oncological outcomes, in order to fully
assess the effectiveness and the differences between the different surgical approaches.
At present, a multicenter registry may represent the best research tool to assess the role of
minimally invasive approaches by comparing the methods with traditional open surgery.
Therefore, for this project, a large registry will be created by collecting data from the
different participating centers to create a working basis for analyzing outcomes of interest
and obtaining directions for further investigation.
The data collected will clarify the role of laparoscopic and robotic surgery versus the open
approach in terms of:
- safety and feasibility based on the intraoperative outcomes
- respect of oncological principles in relation to the stage and location of the tumor
- recovery of gastrointestinal function considering the outcomes measured during the
postoperative hospital stay
- incidence, types and severity of postoperative complications
- overall survival and disease-free survival
Duration of study:
The beginning of the trial is scheduled for January 2015. It is expected to end the chart
review within one year.
Type of data collection:
In the present study, the following information will be collected:
- Patient Demographics
- Surgical Procedure details
- Tumor characteristics
- Operative findings
- Post-operative clinical findings
- Post-operative complications
- Follow-up details
Statistical analysis:
The dichotomous variables will be expressed as numbers and percentages, while continuous
variables will be expressed as mean and standard deviation (SD) or median and interquartile
range (minimum and maximum values).
Continuous variables, will be compared using one-way ANOVA with post hoc multiple comparison
by Tukey's procedure. Pearson's χ2 test or Fisher's exact test, as appropriate, will be used
for analysis of categorical data.
For each of these tests a value of alpha (α) < 0.05 will be considered statistically
significant.
Potential risks and safety management:
Participation in the research registry involves the potential risks of a breach of
confidentiality of the medical record information and associated privacy of the participants.
Such risks will be minimized by the use and the establishment of appropriate information
technology services.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05551416 -
The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
|
||
| Completed |
NCT05518929 -
Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients
|
Phase 4 | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03219593 -
Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
| Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
| Recruiting |
NCT05536102 -
The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
|
Phase 2 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
| Active, not recruiting |
NCT04082364 -
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
|
Phase 2/Phase 3 | |
| Withdrawn |
NCT03766607 -
Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer
|
Phase 2 | |
| Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
| Completed |
NCT01924533 -
Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.
|
Phase 3 | |
| Terminated |
NCT01641939 -
A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
| Active, not recruiting |
NCT04908813 -
Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04249739 -
Pembrolizumab + Capecitabine/Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive
|
Phase 2 | |
| Recruiting |
NCT05514158 -
To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)
|
Phase 1 | |
| Recruiting |
NCT04931654 -
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 |